Elios' dendritic cell vaccine leads to no significant difference in recurrence in Phase IIb for melanoma

Elios Therapeutics LLC (Austin, Texas) reported interim data from 120 patients with stage III or IV resected melanoma

Read the full 186 word article

User Sign In